{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T08:11:01Z","timestamp":1773994261777,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/2.0"},{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/2.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1007\/s10096-010-1007-y","type":"journal-article","created":{"date-parts":[[2010,7,31]],"date-time":"2010-07-31T17:06:44Z","timestamp":1280596004000},"page":"1361-1367","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["In vitro and in vivo activities of linezolid alone and combined with vancomycin and imipenem against Staphylococcus aureus with reduced susceptibility to glycopeptides"],"prefix":"10.1007","volume":"29","author":[{"given":"S.","family":"Ribes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. E.","family":"Pach\u00f3n-Ib\u00e1\u00f1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. A.","family":"Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Tubau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Ariza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Gudiol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Cabellos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,8,1]]},"reference":[{"key":"1007_CR1","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.1001\/jama.290.22.2976","volume":"290","author":"TS Naimi","year":"2003","unstructured":"Naimi TS, LeDell KH, Como-Sabetti K, Borchardt SM, Boxrud DJ, Etienne J et al (2003) Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 290:2976\u20132984","journal-title":"JAMA"},{"key":"1007_CR2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1086\/345476","volume":"36","author":"SE Cosgrove","year":"2003","unstructured":"Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y (2003) Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 36:53\u201359","journal-title":"Clin Infect Dis"},{"key":"1007_CR3","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1093\/jac\/40.1.135","volume":"40","author":"K Hiramatsu","year":"1997","unstructured":"Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC (1997) Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 40:135\u2013136","journal-title":"J Antimicrob Chemother"},{"key":"1007_CR4","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1128\/JCM.01262-06","volume":"45","author":"Y Maor","year":"2007","unstructured":"Maor Y, Rahav G, Belausov N, Ben-David D, Smollan G, Keller N (2007) Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center. J Clin Microbiol 45:1511\u20131514","journal-title":"J Clin Microbiol"},{"key":"1007_CR5","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1128\/AAC.43.7.1747","volume":"43","author":"MW Climo","year":"1999","unstructured":"Climo MW, Patron RL, Archer GL (1999) Combinations of vancomycin and beta-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin. Antimicrob Agents Chemother 43:1747\u20131753","journal-title":"Antimicrob Agents Chemother"},{"key":"1007_CR6","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1089\/mdr.2004.10.346","volume":"10","author":"A Domenech","year":"2004","unstructured":"Domenech A, Ribes S, Cabellos C, Dom\u00ednguez MA, Montero A, Li\u00f1ares J et al (2004) A mouse peritonitis model for the study of glycopeptide efficacy in GISA infections. Microb Drug Resist 10:346\u2013353","journal-title":"Microb Drug Resist"},{"key":"1007_CR7","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1128\/AAC.47.4.1262-1266.2003","volume":"47","author":"MR Moore","year":"2003","unstructured":"Moore MR, Perdreau-Remington F, Chambers HF (2003) Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis. Antimicrob Agents Chemother 47:1262\u20131266","journal-title":"Antimicrob Agents Chemother"},{"key":"1007_CR8","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1016\/S0140-6736(99)01017-X","volume":"8","author":"J Ariza","year":"1999","unstructured":"Ariza J, Pujol M, Cabo J, Pe\u00f1a C, Fern\u00e1ndez N, Li\u00f1ares J et al (1999) Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet 8:1587\u20131588","journal-title":"Lancet"},{"key":"1007_CR9","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1128\/AAC.45.4.1292-1294.2001","volume":"45","author":"N Aritaka","year":"2001","unstructured":"Aritaka N, Hanaki H, Cui L, Hiramatsu K (2001) Combination effect of vancomycin and beta-lactams against a Staphylococcus aureus strain, Mu3, with heterogeneous resistance to vancomycin. Antimicrob Agents Chemother 45:1292\u20131294","journal-title":"Antimicrob Agents Chemother"},{"key":"1007_CR10","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/j.1198-743X.2004.00856.x","volume":"10","author":"FW Goldstein","year":"2004","unstructured":"Goldstein FW, Atoui R, Ben Ali A, Nguyen JC, Ly A, Kitzis MD (2004) False synergy between vancomycin and beta-lactams against glycopeptide-intermediate Staphylococcus aureus (GISA) caused by inappropriate testing methods. Clin Microbiol Infect 10:342\u2013345","journal-title":"Clin Microbiol Infect"},{"key":"1007_CR11","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1592\/phco.27.2.227","volume":"27","author":"RH Drew","year":"2007","unstructured":"Drew RH (2007) Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections. Pharmacotherapy 27:227\u2013249","journal-title":"Pharmacotherapy"},{"key":"1007_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10096-007-0389-y","volume":"27","author":"JR Lentino","year":"2008","unstructured":"Lentino JR, Narita M, Yu VL (2008) New antimicrobial agents as therapy for resistant gram-positive cocci. Eur J Clin Microbiol Infect Dis 27:3\u201315","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"1007_CR13","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1128\/AAC.44.4.1062-1066.2000","volume":"44","author":"MJ Rybak","year":"2000","unstructured":"Rybak MJ, Hershberger E, Moldovan T, Grucz RG (2000) In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin\u2013dalfopristin against Staphylococci and Enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob Agents Chemother 44:1062\u20131066","journal-title":"Antimicrob Agents Chemother"},{"key":"1007_CR14","doi-asserted-by":"publisher","first-page":"525","DOI":"10.2165\/00003495-200161040-00008","volume":"61","author":"CM Perry","year":"2001","unstructured":"Perry CM, Jarvis B (2001) Linezolid: a review of its use in the management of serious gram-positive infections. Drugs 61:525\u2013551","journal-title":"Drugs"},{"key":"1007_CR15","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1086\/318486","volume":"32","author":"E Rubinstein","year":"2001","unstructured":"Rubinstein E, Cammarata S, Oliphant T, Wunderink R (2001) Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 32:402\u2013412","journal-title":"Clin Infect Dis"},{"key":"1007_CR16","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1086\/340353","volume":"34","author":"DL Stevens","year":"2002","unstructured":"Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B (2002) Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 34:1481\u20131490","journal-title":"Clin Infect Dis"},{"key":"1007_CR17","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.diagmicrobio.2007.06.001","volume":"59","author":"RN Jones","year":"2007","unstructured":"Jones RN, Fritsche TR, Sader HS, Ross JE (2007) Zyvox Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries. Diagn Microbiol Infect Dis 59:199\u2013209","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1007_CR18","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1093\/jac\/dkg104","volume":"51","author":"P Wilson","year":"2003","unstructured":"Wilson P, Andrews JA, Charlesworth R, Walesby R, Singer M, Farrell DJ et al (2003) Linezolid resistance in clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 51:186\u2013188","journal-title":"J Antimicrob Chemother"},{"key":"1007_CR19","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1128\/AAC.01242-06","volume":"51","author":"C Jacqueline","year":"2007","unstructured":"Jacqueline C, Caillon J, Le Mabecque V, Mi\u00e8geville AF, Hamel A, Bugnon D et al (2007) In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model. Antimicrob Agents Chemother 51:3397\u20133400","journal-title":"Antimicrob Agents Chemother"},{"key":"1007_CR20","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.jss.2006.10.003","volume":"139","author":"M Sacar","year":"2007","unstructured":"Sacar M, Sacar S, Kaleli I, Onem G, Turgut H, Goksin I et al (2007) Linezolid alone and in combination with rifampicin prevents experimental vascular graft infection due to methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis. J Surg Res 139:170\u2013175","journal-title":"J Surg Res"},{"key":"1007_CR21","unstructured":"Clinical and Laboratory Standards Institute (CLSI) (2005) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A6, 6th ed. CLSI, Wayne, PA"},{"issue":"Suppl 2","key":"1007_CR22","first-page":"ii17","volume":"51","author":"AP MacGowan","year":"2003","unstructured":"MacGowan AP (2003) Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother 51(Suppl 2):ii17\u2013ii25","journal-title":"J Antimicrob Chemother"},{"key":"1007_CR23","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1093\/jac\/dki294","volume":"56","author":"A Domenech","year":"2005","unstructured":"Domenech A, Ribes S, Cabellos C, Taberner F, Tubau F, Dom\u00ednguez MA et al (2005) Experimental study on the efficacy of combinations of glycopeptides and beta-lactams against Staphylococcus aureus with reduced susceptibility to glycopeptides. J Antimicrob Chemother 56:709\u2013716","journal-title":"J Antimicrob Chemother"},{"key":"1007_CR24","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1128\/AAC.46.5.1345-1351.2002","volume":"46","author":"MJ Gentry-Nielsen","year":"2002","unstructured":"Gentry-Nielsen MJ, Olsen KM, Preheim LC (2002) Pharmacodynamic activity and efficacy of linezolid in a rat model of pneumococcal pneumonia. Antimicrob Agents Chemother 46:1345\u20131351","journal-title":"Antimicrob Agents Chemother"},{"key":"1007_CR25","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1128\/AAC.41.9.1910","volume":"41","author":"JD Knudsen","year":"1997","unstructured":"Knudsen JD, Fuursted K, Espersen F, Frimodt-M\u00f8ller N (1997) Activities of vancomycin and teicoplanin against penicillin-resistant pneumococci in vitro and in vivo and correlation to pharmacokinetic parameters in the mouse peritonitis model. Antimicrob Agents Chemother 41:1910\u20131915","journal-title":"Antimicrob Agents Chemother"},{"key":"1007_CR26","doi-asserted-by":"publisher","first-page":"4011","DOI":"10.1128\/AAC.00523-06","volume":"50","author":"O Murillo","year":"2006","unstructured":"Murillo O, Dom\u00e9nech A, Garcia A, Tubau F, Cabellos C, Gudiol F et al (2006) Efficacy of high doses of levofloxacin in experimental foreign-body infection by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents and Chemother 50:4011\u20134017","journal-title":"Antimicrob Agents and Chemother"},{"key":"1007_CR27","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1128\/AAC.36.10.2085","volume":"36","author":"D Paradis","year":"1992","unstructured":"Paradis D, Vall\u00e9e F, Allard S, Bisson C, Daviau N, Drapeau Ch et al (1992) Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin. Antimicrob Agents Chemother 36:2085\u20132092","journal-title":"Antimicrob Agents Chemother"},{"key":"1007_CR28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1128\/AAC.49.1.45-51.2005","volume":"49","author":"C Jacqueline","year":"2005","unstructured":"Jacqueline C, Navas D, Batard E, Mi\u00e8geville AF, Le Mabecque V, Kergueris MF et al (2005) In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 49:45\u201351","journal-title":"Antimicrob Agents Chemother"},{"key":"1007_CR29","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1093\/jac\/dkg160","volume":"51","author":"C Jacqueline","year":"2003","unstructured":"Jacqueline C, Caillon J, Le Mabecque V, Mi\u00e8geville AF, Donnio PY, Bugnon D et al (2003) In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time\u2013kill curve methods. J Antimicrob Chemother 51:857\u2013864","journal-title":"J Antimicrob Chemother"},{"key":"1007_CR30","first-page":"252","volume":"19","author":"JM Sahuquillo Arce","year":"2006","unstructured":"Sahuquillo Arce JM, Colombo Gainza E, Gil Brusola A, Ortiz Est\u00e9vez R, Cant\u00f3n E, Gobernado M (2006) In vitro activity of linezolid in combination with doxycycline, fosfomycin, levofloxacin, rifampicin and vancomycin against methicillin-susceptible Staphylococcus aureus. Rev Esp Quimioter 19:252\u2013257","journal-title":"Rev Esp Quimioter"},{"key":"1007_CR31","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1128\/AAC.46.8.2606-2612.2002","volume":"46","author":"GP Allen","year":"2002","unstructured":"Allen GP, Cha R, Rybak MJ (2002) In vitro activities of quinupristin\u2013dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 46:2606\u20132612","journal-title":"Antimicrob Agents Chemother"},{"key":"1007_CR32","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S0140-6736(01)05410-1","volume":"358","author":"S Tsiodras","year":"2001","unstructured":"Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, Venkataraman L et al (2001) Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358:207\u2013208","journal-title":"Lancet"},{"key":"1007_CR33","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1128\/AAC.36.5.907","volume":"36","author":"B Fantin","year":"1992","unstructured":"Fantin B, Carbon C (1992) In vivo antibiotic synergism: contribution of animal models. Antimicrob Agents Chemother 36:907\u2013912","journal-title":"Antimicrob Agents Chemother"},{"key":"1007_CR34","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1469-0691.2005.01162.x","volume":"11","author":"BA Cunha","year":"2005","unstructured":"Cunha BA (2005) Methicillin-resistant Staphylococcus aureus: clinical manifestations and antimicrobial therapy. Clin Microbiol Infect 11:33\u201342","journal-title":"Clin Microbiol Infect"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-010-1007-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-010-1007-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s10096-010-1007-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-010-1007-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T21:04:18Z","timestamp":1630443858000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-010-1007-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,1]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["1007"],"URL":"https:\/\/doi.org\/10.1007\/s10096-010-1007-y","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,1]]},"assertion":[{"value":"25 August 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}